President Donald Trump is considering moving marijuana from Schedule I to Schedule III under federal law, a change that could ease restrictions but trigger intense political, economic, and legal consequences.
At a Glance
- Cannabis has been a Schedule I drug under U.S. law since 1970.
- Trump is weighing reclassification to Schedule III following industry lobbying.
- Biden-era rescheduling review was left unfinished when Trump took office.
- Medical marijuana is legal in 40 states; recreational use in 24 states plus D.C.
- No executive action has been announced as internal White House reviews continue.
Trump Weighs Rescheduling Amid Industry Pressure
At recent public appearances, Trump indicated openness to reclassifying marijuana, a move that would recognize its medical uses while keeping it under controlled substance regulations. Such a shift could open the door for expanded research, easier access for patients, and reduced barriers for cannabis-related businesses.
Cannabis industry leaders, including Trulieve CEO Kim Rivers, have lobbied extensively for reform, supporting political action committees and engaging directly with Trump at events. Advocates emphasize potential economic growth and tax revenue, while critics question the role of financial contributions in shaping drug policy.
Watch now: Trump’s Marijuana Policy Shift Explained · YouTube
Historical Context and Legal Landscape
Since its placement in Schedule I under the Controlled Substances Act of 1970, marijuana has been grouped with substances considered to have high abuse potential and no accepted medical use. Growing bipartisan support for reform has not yet translated into a permanent federal change, with Biden’s rescheduling proposal stalling before completion.
As of August 2025, medical marijuana is legal in 40 states and Washington, D.C., while 24 states plus D.C. allow recreational use. Federal prohibition continues to create legal and financial complications for businesses, impede banking access, and fuel disputes over states’ rights. The Trump administration’s decision will be informed by agency reports requested by White House Chief of Staff Susie Wiles, but no clear timeline has been set.
Economic, Social, and Enforcement Impacts
Rescheduling cannabis could reshape multiple sectors. Financial institutions would be able to serve cannabis businesses without fear of federal penalties, investment could flow more freely, and job creation could accelerate. Pharmaceutical and agricultural industries may expand cannabis research and product development.
Law enforcement agencies could see reductions in marijuana-related arrests and prosecutions, freeing resources for other priorities. However, opponents cite concerns about public health, youth access, and the possibility of expanded recreational use.
Politically, the move could attract younger and independent voters ahead of the 2026 midterms. It may also encourage bipartisan cooperation on drug policy reform, though it risks alienating socially conservative constituents. The decision will test the administration’s ability to balance economic opportunity, public health, and political calculation in a closely divided national climate.
